Cargando…
Dupilumab: An emerging therapy in allergic fungal rhinosinusitis()
Allergic fungal rhinosinusitis (AFRS) is a highly resistant disease and is challenging to treat. Patients with recurrent attacks of the disease despite surgical management can benefit from biologics as adjunct therapies. Dupilumab has shown promising endpoints in patients with chronic rhinosinusitis...
Autores principales: | Bulkhi, Adeeb A., Mirza, Ahmad A., Aburiziza, Abdullah J., Marglani, Osama A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
World Allergy Organization
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9023893/ https://www.ncbi.nlm.nih.gov/pubmed/35497650 http://dx.doi.org/10.1016/j.waojou.2022.100638 |
Ejemplares similares
-
Successful Use of Dupilumab as a Salvage Therapy for Recalcitrant Allergic Fungal Rhinosinusitis: A Case Report
por: Mujahed, Revan A, et al.
Publicado: (2022) -
A case report of allergic fungal rhinosinusitis managed with Dupilumab
por: Alotaibi, Naif H., et al.
Publicado: (2021) -
Current understanding of allergic fungal rhinosinusitis
por: Tyler, Matthew A., et al.
Publicado: (2018) -
Real-world evidence for the effectiveness and safety of dupilumab in patients with CRSwNP after 1 year of therapy
por: Albrecht, Tobias, et al.
Publicado: (2023) -
Allergic fungal sinusitis eroding the pterygoid plates: a rare case series()
por: Marglani, Osama, et al.
Publicado: (2014)